Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced and relapsed or refractory solid tumor or lymphoma
Protocol ID
MSD MK-3475-051
Disease (Sub Disease)
Solid Tumour
Lymphoma
Diagnosis Stage
Relapse/ refractory
Location
NSW, QLD
Sponsor
Merck Sharp & Dohme Corp.
Trial Status
Open
Sites
The Children's Hospital at Westmead
Queensland Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
6 months to 17 years
International registry ID's
NCT02332668
Back to Registry
Study Title A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced and relapsed or refractory solid tumor or lymphoma
Protocol ID MSD MK-3475-051
Disease (Sub Disease) Solid Tumour
Lymphoma
Diagnosis Stage Relapse/ refractory
Location NSW / QLD
Sponsor Merck Sharp & Dohme Corp.
Links https://clinicaltrials.gov/ct2/show/NCT02332668
Trial Status Open
Trial Open Date 04/04/2016
Sites The Children's Hospital at Westmead / Queensland Children's Hospital
Study Type Treatment
Phase Phase 1/2
Age Eligibility 6 months to 17 years
International registry ID's NCT02332668